Crispr Therapeutics shares tumble after significant earnings miss
Director Timothy J. Jahnke of Zurn Elkay Water Solutions Corp (NYSE:ZWS) sold a total of 30,000 shares of common stock in two separate transactions, netting approximately $1.3 million. The sales come as ZWS shares trade near their 52-week high of $44.98, having surged nearly 17% in the past week. According to InvestingPro analysis, the stock is currently showing signs of being overbought.
On July 30, 2025, Jahnke sold 10,000 shares of Zurn Elkay Water Solutions at a price of $42.59, totaling $425,900. The prices for these sales ranged from $42.50 to $43.23. Following this transaction, Jahnke directly owns 338,964 shares of the company.
The following day, July 31, 2025, Jahnke sold 20,000 shares at a price of $43.73, amounting to $874,599. These sales were executed at prices ranging from $43.74 to $43.77. These shares were held indirectly by an irrevocable trust. After this transaction, the irrevocable trust holds 180,000 shares.
The initial sale was executed pursuant to a Rule 10b5-1 plan.
In other recent news, Zurn Water Solutions reported robust financial results for the second quarter of 2025, surpassing earnings expectations. The company achieved earnings per share of $0.42, exceeding the forecasted $0.36, which represents a 16.67% surprise. Additionally, Zurn’s revenue reached $445 million, surpassing the predicted $424.61 million. These results have been well-received by investors. Mizuho (NYSE:MFG) has responded by raising its price target for Zurn Water Solutions to $43, up from $36, while maintaining a Neutral rating. The firm highlighted the company’s strong second-quarter performance, driven by tariff mitigation and organic sales growth of 8%. This growth is anticipated to continue into the third quarter. These developments reflect the company’s positive momentum in the market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.